Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III Melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol. 2020;38:3925–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:1465–77.

Article  CAS  PubMed  Google Scholar 

Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399:1718–29.

Article  CAS  PubMed  Google Scholar 

Ascierto PA, Kirkwood JM, Grob J-J, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage iii melanoma. N Engl J Med. 2020;383:1139–48.

Article  CAS  PubMed  Google Scholar 

Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1435–48.

Article  CAS  PubMed  Google Scholar 

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma | NEJM Evidence [Internet]. [cited 2022 Sep 20]. https://doi.org/10.1056/EVIDoa2200214.

Eggermont AM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV, et al. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. Eur J Cancer. 2021;158:156–68.

Article  CAS  PubMed  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.

Article  PubMed  PubMed Central  Google Scholar 

Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Ann Oncol. 2020;31:1075–82.

Article  CAS  PubMed  Google Scholar 

Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22:836–47.

Article  CAS  PubMed  Google Scholar 

Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, et al. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. Br J Cancer. 2021;124:574–80.

Article  CAS  PubMed  Google Scholar 

Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Phase II study SECOMBIT (sequential combo immuno and target therapy study): a subgroup analysis with a longer follow-up. JCO Wolters Kluwer. 2022;40:9535–9535.

Google Scholar 

Ascierto PA, Mandala M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation. Annals of Oncology Elsevier. 2022;33:S1408–9.

Article  Google Scholar 

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134. J Clini Oncology. 2022. https://doi.org/10.1200/JCO.2021.39.36_suppl.356154cited 2022 Sep 14

Lau PKH, Feran B, Smith L, Lasocki A, Molania R, Smith K, et al. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). J Immunother Cancer. 2021;9: e002995.

Article  PubMed  PubMed Central  Google Scholar 

Reijers ILM, Rozeman EA, Wilgenhof S, van Thienen JV, Haanen JBAG, Blank CU. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma. Pigment Cell Melanoma Res. 2020;33:498–506.

Article  CAS  PubMed  Google Scholar 

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672–81.

Article  CAS  PubMed  Google Scholar 

Marquez-Rodas I, Guerrero MAB, Couselo EM, Soria A, Cerezuela-Fuentes P, Mozo JLM, et al. 848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801. Annals of Oncology Elsevier. 2022;33:S937–8.

Article  Google Scholar 

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

AWeber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023:41(3):517–527. https://doi.org/10.1200/JCO.22.00533.

Augustin RC, Luke JJ. Induction exposure dose of ipilimumab and failure of adjuvant nivolumab plus ipilimumab in melanoma. J Clin Oncol. 2023;41(3):443-446. https://doi.org/10.1200/JCO.22.01770.

Versluis JM, Hendriks AM, Weppler AM, Brown LJ, de Joode K, Suijkerbuijk KPM, et al. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: a multicentre retrospective analysis. Eur J Cancer. 2021;151:72–83.

Article  CAS  PubMed  Google Scholar 

Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1449–61.

Article  CAS  PubMed  Google Scholar 

Malissen N, Grob J-J. Metastatic melanoma: recent therapeutic progress and future perspectives. Drugs. 2018;78:1197–209.

Article  CAS  PubMed  Google Scholar 

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386:24–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ascierto PA, Bono P, Bhatia S, Melero I, Nyakas MS, Svane I-M, et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Annals of Oncology Elsevier. 2017;28:v611–2.

Article  Google Scholar 

Inozume T, Hanada K-I, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010;33:956–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang N-AAS, Andrews MC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170:1120-11331.e17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gajewski TF, Fallarino F, Fields PE, Rivas F, Alegre ML. Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol. 2001;166:3900–7.

Article  CAS  PubMed  Google Scholar 

Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Budimir N, Thomas GD, Dolina JS, Salek-Ardakani S. Reversing T-cell exhaustion in cancer: lessons learned from Pd-1/Pd-l1 immune checkpoint blockade. Cancer Immunol Res. 2022;10:146–53.

Article  CAS  PubMed  Google Scholar 

O’Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD-1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81.

Article  PubMed  Google Scholar 

Charles J, Chaperot L, Hannani D, Bruder Costa J, Templier I, Trabelsi S, et al. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. Oncoimmunology. 2020;9:1738812.

Article  PubMed  PubMed Central  Google Scholar 

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111.

Article  CAS  PubMed  Google Scholar 

Baruch EN, Berg AL, Besser MJ, Schachter J, Markel G. Adoptive T cell therapy: An overview of obstacles and opportunities. Cancer. 2017;123:2154–62.

Article  PubMed  Google Scholar 

Haanen JBAG, Rohaan M, Borch TH, van den Berg JH, Met Ö, Foppen MG, et al. LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: results from a multicenter, randomized phase III trial. Ann Oncol. 2022;33:S1406.